{"id":1188,"date":"2020-05-08T14:43:57","date_gmt":"2020-05-08T14:43:57","guid":{"rendered":"https:\/\/areyoucovidmune.com\/covidmune\/?page_id=1188"},"modified":"2020-05-08T15:43:49","modified_gmt":"2020-05-08T15:43:49","slug":"covid-19-clinical-trials","status":"publish","type":"page","link":"https:\/\/areyoucovidmune.com\/covidmune\/covid-19-clinical-trials\/","title":{"rendered":"Covid-19 Clinical Trials"},"content":{"rendered":"

[et_pb_section fb_built=”1″ fullwidth=”on” _builder_version=”3.19.3″ background_image=”https:\/\/areyoucovidmune.com\/covidmune\/wp-content\/uploads\/2019\/11\/shutterstock_112250879.jpg” custom_padding=”0px|0px|0|0px|false|false”][et_pb_fullwidth_header title=”Are You CovidMune?™” text_orientation=”center” _builder_version=”3.19.3″ title_level=”h2″ title_font=”|800|||on|||#e02b20|” title_text_color=”#ffffff” content_font=”|700|||||||” content_text_color=”#000000″ subhead_font=”||||on|||#e02b20|” subhead_text_color=”#ffffff” subhead_font_size=”30px” background_image=”https:\/\/areyoucovidmune.com\/covidmune\/wp-content\/uploads\/2020\/04\/covid-19-dna.jpg” custom_button_one=”on” button_one_text_color=”#ffffff” button_one_border_color=”#e02b20″ button_one_font=”|600|||||||” box_shadow_style_button_one=”preset2″][\/et_pb_fullwidth_header][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”3.19.3″ custom_padding=”7px|0px|0|0px|false|false”][et_pb_row _builder_version=”3.19.3″][et_pb_column type=”4_4″ _builder_version=”3.19.3″ parallax=”off” parallax_method=”on”][et_pb_text _builder_version=”3.19.3″]<\/p>\n

Covid-19 Clinical Trials Sampling<\/span><\/u><\/b><\/span><\/h4>\n

This represents a sampling of the first 30 clinical trials listed on clinical trials.gov specific to cover-19 investigations. Twenty out of the thirty proposed trials has direct<\/g> correlation to the protein NLRP3 with the drugs and treatments listed to be used in these studies<\/span>.<\/span><\/p>\n

Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial. (C-19-ACS)<\/strong><\/span><\/p>\n

https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04333407?cond=COVID-19&draw=3&rank=15<\/a><\/p>\n

Condition or disease COVID-19<\/p>\n

Drug: Aspirin 75mg \u2013 940 papers on NLRP3<\/strong>
https:\/\/www.ncbi.nlm.nih.gov\/pmc\/?term=aspirin+and+NLRP3<\/a><\/p>\n

Drug: Clopidogrel 75mg \u2013 140 papers on NLRP3<\/strong>
<\/a>https:\/\/www.ncbi.nlm.nih.gov\/pmc\/?term=Clopidogrel+and+NLRP3<\/a><\/p>\n

Drug: Rivaroxaban 2.5 MG \u2013 22 papers on NLRP3<\/strong>
https:\/\/www.ncbi.nlm.nih.gov\/pmc\/?term=Rivaroxaban+and+NLRP3<\/a><\/p>\n

<\/a>Drug: Atorvastatin 40mg \u2013 528 papers on NLRP3<\/strong>
https:\/\/www.ncbi.nlm.nih.gov\/pmc\/?term=Atorvastatin+and+NLRP3<\/a><\/p>\n

Drug: Omeprazole 20mg \u2013 74 papers on NLRP3<\/strong>
https:\/\/www.ncbi.nlm.nih.gov\/pmc\/?term=Omeprazole+and+NLRP3<\/a><\/p>\n

Duvelisib to Combat COVID-19<\/strong><\/span><\/p>\n

https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04372602?cond=COVID-19&draw=2&rank=1<\/a><\/p>\n

Condition or disease COVID-19<\/p>\n

Drug: Duvelisib \u2013 2 papers on NLRP3<\/strong>
https:\/\/www.ncbi.nlm.nih.gov\/pmc\/?term=Duvelisib+and+NLRP3<\/a><\/p>\n

Application of Desferal to Treat COVID-19<\/strong><\/span><\/p>\n

https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04333550?cond=COVID-19&draw=2&rank=3<\/a><\/p>\n

Condition or disease COVID-19<\/p>\n

Drug: Deferoxamine \u2013 135 papers on NLRP3<\/strong>
https:\/\/www.ncbi.nlm.nih.gov\/pmc\/?term=Deferoxamine+and+NLRP3<\/a><\/p>\n

<\/a>Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19<\/strong><\/span><\/p>\n

https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04336904?cond=COVID-19&draw=2&rank=4<\/a><\/p>\n

Condition or disease COVID-19<\/p>\n

Drug: Favipiravir \u2013 19 papers on NLRP3<\/strong>
https:\/\/www.ncbi.nlm.nih.gov\/pmc\/?term=Favipiravir+and+NLRP3<\/a><\/p>\n

Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalised COVID-19 Patients With High Risk of Progression<\/strong><\/span><\/p>\n

https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04345445?cond=COVID-19&draw=2&rank=7<\/a><\/p>\n

Condition or disease COVID-19<\/p>\n

Drug: Tocilizumab \u2013 307 papers on NLRP3<\/strong>
https:\/\/www.ncbi.nlm.nih.gov\/pmc\/?term=Tocilizumab+and+NLRP3<\/a><\/p>\n

Drug: Methylprednisolone \u2013 260 papers on NLRP3<\/strong>
https:\/\/www.ncbi.nlm.nih.gov\/pmc\/?term=Methylprednisolone+and+NLRP3<\/a><\/p>\n

Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia<\/strong><\/span><\/p>\n

https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04359095?cond=COVID-19&draw=2&rank=8<\/a><\/p>\n

Condition or disease COVID-19<\/p>\n

Drug: Hydroxychloroquine \u2013 254 papers on NLRP3<\/strong>
https:\/\/www.ncbi.nlm.nih.gov\/pmc\/?term=Hydroxychloroquine+and+NLRP3<\/a><\/p>\n

Drug: Lopinavir Pill \u2013 48 papers on NLRP3<\/strong>
https:\/\/www.ncbi.nlm.nih.gov\/pmc\/?term=Lopinavir+and+NLRP3<\/a><\/p>\n

Drug: Ritonavir Pill \u2013 75 papers on NLRP3<\/strong>
https:\/\/www.ncbi.nlm.nih.gov\/pmc\/?term=Ritonavir+and+NLRP3<\/a><\/p>\n

Drug: Azithromycin \u2013 206 papers on NLRP3<\/strong>
https:\/\/www.ncbi.nlm.nih.gov\/pmc\/?term=Azithromycin+and+NLRP3<\/a><\/p>\n

Isotretinoin in Treatment of COVID-19 (Randomized)<\/strong><\/span><\/p>\n

https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04361422?cond=COVID-19&draw=2&rank=9<\/a><\/p>\n

Condition or disease COVID-19<\/p>\n

Drug: Isotretinoin \u2013 44 papers on NLRP3<\/strong>
https:\/\/www.ncbi.nlm.nih.gov\/pmc\/?term=Isotretinoin+and+NLRP3<\/a><\/p>\n

The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19<\/strong><\/span><\/p>\n

https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04347915?cond=COVID-19&draw=2&rank=13<\/a><\/p>\n

Condition or disease COVID-19<\/p>\n

Drug: Clevudine \u2013 2 papers on NLRP3<\/strong>
https:\/\/www.ncbi.nlm.nih.gov\/pmc\/?term=Clevudine+and+NLRP3<\/a><\/p>\n

Drug: Hydroxychloroquine – 254 papers on NLRP3<\/strong>
https:\/\/www.ncbi.nlm.nih.gov\/pmc\/?term=Hydroxychloroquine+and+NLRP3<\/a><\/p>\n

Hyperbaric Oxygen Therapy (HBOT) as a Treatment for COVID-19 (COVID-19) Infection<\/strong><\/span><\/p>\n

https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04343183?cond=COVID-19&draw=2&rank=14<\/a><\/p>\n

Condition or disease COVID-19<\/p>\n

Device: Hyperbaric Oxygen Therapy \u2013 169 papers on NLRP3<\/strong>
https:\/\/www.ncbi.nlm.nih.gov\/pmc\/?term=Hyperbaric+Oxygen+and+NLRP3<\/a><\/p>\n

The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19<\/strong><\/span><\/p>\n

https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04291053?cond=COVID-19&draw=2&rank=17<\/a><\/p>\n

Condition or disease COVID-19<\/p>\n

Drug: Huaier Granule – 3 papers on NLRP3<\/strong>
<\/a><\/a><\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pmc\/?term=Huaier+Granule+and+NLRP3<\/a><\/p>\n

The Role of Resistant Starch in COVID-19 Infection<\/span>\u00a0<\/strong><\/p>\n

https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04342689?cond=COVID-19&draw=2&rank=19<\/a><\/p>\n

Condition or disease COVID-19<\/p>\n

Drug: Dietary Supplement containing resistant starch – 197 papers on NLRP3<\/strong>
https:\/\/www.ncbi.nlm.nih.gov\/pmc\/?term=resistant+starch+and+NLRP3<\/a><\/p>\n

Dietary Supplement: Placebo Starch – 105 papers on NLRP3<\/strong>
https:\/\/www.ncbi.nlm.nih.gov\/pmc\/?term=placebo+starch+and+NLRP3<\/a><\/p>\n

Hydrogen-Oxygen Generator With Nebulizer in the Improvement of Symptoms in Patients Infected With COVID-19 (COVID-19)<\/strong><\/span><\/p>\n

https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04336462?cond=COVID-19&draw=2&rank=18<\/a><\/p>\n

Condition or disease COVID-19<\/p>\n

Device: oxyhydrogen – no papers<\/p>\n

Device: Oxygen – 11,740 papers on NLRP3<\/strong>
https:\/\/www.ncbi.nlm.nih.gov\/pmc\/?term=oxygen+and+NLRP3<\/a><\/p>\n

Study of FT516 for the Treatment of COVID-19 in Hospitalized Patients With Hypoxia<\/strong><\/span><\/p>\n

https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04363346?cond=COVID-19&draw=2&rank=21<\/a><\/p>\n

Condition or disease COVID-1<\/p>\n

Drug: FT516 (NK cells) – 5,110 papers on NLRP3<\/strong>
https:\/\/www.ncbi.nlm.nih.gov\/pmc\/?term=NK+cells+and+NLRP3<\/a><\/p>\n

DAS181 for Severe COVID-19: Compassionate Use<\/strong><\/span><\/p>\n

https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04324489?cond=COVID-19&draw=2&rank=22<\/a><\/p>\n

Condition or disease COVID-19<\/p>\n

Drug: DAS181 – 10 papers on NLRP3<\/strong>
https:\/\/www.ncbi.nlm.nih.gov\/pmc\/?term=DAS181+and+NLRP3<\/a><\/p>\n

Anti-inflammatory\/Antioxidant Oral Nutrition Supplementation in COVID-19 (ONSCOVID19)<\/strong><\/span><\/p>\n

https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04323228?cond=COVID-19&draw=2&rank=24<\/a><\/p>\n

Condition or disease COVID-19<\/p>\n

Dietary Supplement: oral nutrition supplement (ONS) enriched in<\/p>\n

\u00a0– eicosapentaenoic acid, – 428 papers on NLRP3<\/strong>
https:\/\/www.ncbi.nlm.nih.gov\/pmc\/?term=eicosapentaenoic+acid+and+NLRP3<\/a><\/p>\n

\u00a0– gamma-linolenic acid and\u00a0 – 178 papers on NLRP3<\/strong>
https:\/\/www.ncbi.nlm.nih.gov\/pmc\/?term=gamma-linolenic+acid+and+NLRP3<\/a><\/p>\n

\u00a0– antioxidants \u2013 2,403 papers on NLRP3<\/strong>
https:\/\/www.ncbi.nlm.nih.gov\/pmc\/?term=antioxidants+and+NLRP3<\/a><\/p>\n

Study of Open Label<\/g> Losartan in COVID-19<\/strong><\/span><\/p>\n

https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04335123?cond=COVID-19&draw=2&rank=27<\/a><\/p>\n

Condition or disease COVID-19<\/p>\n

Drug: Losartan – 206 papers on NLRP3<\/strong>
https:\/\/www.ncbi.nlm.nih.gov\/pmc\/?term=Losartan+and+NLRP3<\/a><\/p>\n

Ivermectin and Nitazoxanide Combination Therapy for COVID-19<\/strong><\/span><\/p>\n

https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04360356?cond=COVID-19&draw=2&rank=29<\/a><\/p>\n

Condition or disease COVID-19<\/p>\n

Combination Product: Ivermectin – 58 papers on NLRP3<\/strong>
https:\/\/www.ncbi.nlm.nih.gov\/pmc\/?term=Ivermectin+and+NLRP3<\/a><\/p>\n

plus Nitazoxanide – 28 papers on NLRP3<\/strong>
https:\/\/www.ncbi.nlm.nih.gov\/pmc\/?term=Nitazoxanide+and+NLRP3<\/a><\/p>\n

Multi-site Adaptive Trials Using Hydroxycholoroquine<\/g> for COVID-19 (MATCH)<\/strong><\/span><\/p>\n

https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04370262?cond=COVID-19&draw=2&rank=30<\/a><\/p>\n

Condition or disease COVID-19<\/p>\n

Drug: HCQ – Hydroxychloroquine \u2013 254 papers on NLRP3<\/strong>
https:\/\/www.ncbi.nlm.nih.gov\/pmc\/?term=Hydroxychloroquine+and+NLRP3<\/a><\/p>\n

+ Intravenous Famotidine – 11 papers on NLRP3<\/strong>
https:\/\/www.ncbi.nlm.nih.gov\/pmc\/?term=Famotidine+and+NLRP3<\/a><\/p>\n

Exchange Transfusion Versus Plasma From Convalescent Patients With Methylene Blue in Patients With COVID-19 (COVID-19)<\/strong><\/span><\/p>\n

https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04376788?cond=COVID-19&draw=2&rank=26<\/a><\/p>\n

Condition or disease COVID-19<\/p>\n

Biological: exchange blood transfusion from normal donor
Biological: plasma from convalescent patients with COVID-19
Drug: Methylene Blue 5 MG\/ML – 282 papers on NLRP3<\/strong>
https:\/\/www.ncbi.nlm.nih.gov\/pmc\/?term=Methylene+Blue+and+NLRP3<\/a><\/p>\n

A Study Evaluating the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 Infection<\/strong><\/span><\/p>\n

https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04354831?cond=COVID-19&draw=2&rank=6<\/a><\/p>\n

Condition or disease COVID-19<\/p>\n

Biological: anti-SARS-CoV-2 convalescent plasma – 84 papers on NLRP3<\/strong>
https:\/\/www.ncbi.nlm.nih.gov\/pmc\/?term=convalescent+plasma+and+NLRP3<\/a><\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

[et_pb_section fb_built=”1″ fullwidth=”on” _builder_version=”3.19.3″ background_image=”https:\/\/areyoucovidmune.com\/covidmune\/wp-content\/uploads\/2019\/11\/shutterstock_112250879.jpg” custom_padding=”0px|0px|0|0px|false|false”][et_pb_fullwidth_header title=”Are You CovidMune?™” text_orientation=”center” _builder_version=”3.19.3″ title_level=”h2″ title_font=”|800|||on|||#e02b20|” title_text_color=”#ffffff” content_font=”|700|||||||” content_text_color=”#000000″ subhead_font=”||||on|||#e02b20|” subhead_text_color=”#ffffff” subhead_font_size=”30px” background_image=”https:\/\/areyoucovidmune.com\/covidmune\/wp-content\/uploads\/2020\/04\/covid-19-dna.jpg” custom_button_one=”on” button_one_text_color=”#ffffff” button_one_border_color=”#e02b20″ button_one_font=”|600|||||||” box_shadow_style_button_one=”preset2″][\/et_pb_fullwidth_header][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”3.19.3″ custom_padding=”7px|0px|0|0px|false|false”][et_pb_row _builder_version=”3.19.3″][et_pb_column type=”4_4″ _builder_version=”3.19.3″ parallax=”off” parallax_method=”on”][et_pb_text _builder_version=”3.19.3″] Covid-19 Clinical Trials Sampling This represents a sampling of the first 30 clinical trials listed on clinical trials.gov specific to cover-19 […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":""},"_links":{"self":[{"href":"https:\/\/areyoucovidmune.com\/covidmune\/wp-json\/wp\/v2\/pages\/1188"}],"collection":[{"href":"https:\/\/areyoucovidmune.com\/covidmune\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/areyoucovidmune.com\/covidmune\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/areyoucovidmune.com\/covidmune\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/areyoucovidmune.com\/covidmune\/wp-json\/wp\/v2\/comments?post=1188"}],"version-history":[{"count":7,"href":"https:\/\/areyoucovidmune.com\/covidmune\/wp-json\/wp\/v2\/pages\/1188\/revisions"}],"predecessor-version":[{"id":1199,"href":"https:\/\/areyoucovidmune.com\/covidmune\/wp-json\/wp\/v2\/pages\/1188\/revisions\/1199"}],"wp:attachment":[{"href":"https:\/\/areyoucovidmune.com\/covidmune\/wp-json\/wp\/v2\/media?parent=1188"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}